Futu news on October 3rd$BETTERS MED (06678.HK)$The dark market opened 1.43% lower, and finally closed down 37.14%, losing HK $1040 per hand.

According to previous public information, the number of applicants for the public placement of Pak Tak Medical was 3350, with a success rate of 100 per cent. Futu Information collates the relevant data as follows:

Investment highlight

Market leader: according to Frost Sullivan, according to the sales revenue and sales of microwave ablation needles in 2021, the company is the largest supplier of microwave ablation medical devices for the treatment of thyroid nodules and breast nodules in China. In addition, in terms of sales revenue in 2021, the company is the third largest supplier of microwave ablation medical devices in China.

Track potential: according to Frost Sullivan, the number of microwave ablation operations in China increased from 70900 in 2016 to 181200 in 2021, and is expected to reach 660000 in 2026, with a compound annual growth rate of 29.6% from 2022 to 2026. In addition, in terms of hospital charges, the size of China's microwave ablation market is expected to increase significantly from 3 billion yuan in 2022 to 9.2 billion yuan in 2026, with a compound annual growth rate of 32.5%.

Risk hint

Relying on third parties: the company used to rely on and predicts that it will continue to rely on third parties to supply direct materials for the manufacture of microwave ablation medical devices, any interference in the production of suppliers or their inability to produce sufficient quantities to meet the company's needs can undermine the company's ability to produce products on schedule.

May not be able to maintain or renew relationships with distributors and customers: the company relies heavily on distributors and distributors to distribute and resell the company's products to hospitals. Any reduction, delay or cancellation of dealer orders, or the Company's failure to renew the agreement with it, may result in sustainable fluctuations or decreases in revenue or growth and have a significant adverse impact on the Company's business, financial condition and results of operations.